Rxivist logo

Rxivist combines preprints from bioRxiv with data from Twitter to help you find the papers being discussed in your field. Currently indexing 67,591 bioRxiv papers from 298,050 authors.

Identification of drug candidates that enhance pyrazinamide activity from a clinical drug library

By Hongxia Niu, Chao Ma, Peng Cui, Wanliang Shi, Shuo Zhang, Jie Feng, David Sullivan, Bingdong Zhu, Wenhong Zhang, Ying Zhang

Posted 04 Mar 2017
bioRxiv DOI: 10.1101/113704 (published DOI: 10.1038/emi.2017.23)

Tuberculosis (TB) remains a leading cause of morbidity and mortality globally. The current TB therapy takes at least 6 months for drug-susceptible TB and 9-24 months for MDR-TB. The lengthy therapy is thought to be due to M. tuberculosis persisters that are not effectively killed by the current TB drugs. However, pyrazinamide (PZA) is an indispensable frontline TB drug that kills M. tuberculosis persisters and plays a critical role in shortening the treatment. In this study, we explored the idea of identifying FDA-approved drugs that enhance PZA activity as a rapid and efficient approach to developing more effective treatment as opposed to new drug development. To achieve that, we screened the clinical drug library and identified various drug candidates that could enhance PZA activity in vitro against a 3-month-old M. tuberculosis culture. These findings are of particular interest and may have implications for improved treatment of drug-susceptible TB and drug-resistant TB. Further studies are needed to determine if these drugs can shorten TB treatment in vivo in animal models and if so in patients.

Download data

  • Downloaded 264 times
  • Download rankings, all-time:
    • Site-wide: 40,574 out of 67,594
    • In microbiology: 2,685 out of 5,468
  • Year to date:
    • Site-wide: 58,798 out of 67,594
  • Since beginning of last month:
    • Site-wide: 57,762 out of 67,594

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide

Sign up for the Rxivist weekly newsletter! (Click here for more details.)